All In Biotech

Drug Trial Radar · NCT01713101

Tranexamic Acid for Upper Gastrointestinal Bleeding

Early Administration of Intravenous Tranexamic Acid for Upper Gastrointestinal Bleeding Prior to Endoscopy

Last checked: Nov 20, 2026Latest source record: May 16, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 414 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

414

Planned (sponsor's estimate)

Start

Oct 2012

Primary completion

Jul 2015

Study completion Aug 2015

Sponsor

Lead sponsor
Seoul National University HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 24, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is to see whether the early intravenous administration of tranexamic acid improves the outcome of acute upper gastrointestinal bleeding.

Conditions

  • Acute Upper Gastrointestinal Hemorrhage

Interventions

  • Early intravenous tranexamic acid administrationDrug

    Initial history taking and physical examination --\> enrollment --\> 1g bolus over 10 minutes followed slow infusion over 8 hours.

  • placeboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of patients requiring early endoscopic treatmentTime frame: Within 24 hours of emergency department visit

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Seoul National University Bundang Hospital

    Seongnam-si, Kyeongi-do, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.